PYPD - Earnings call transcript Q2 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to the PolyPid Second Quarter 2022 Conference Call. [Operator Instructions] A reminder, this call is recorded. And I would now like to introduce your host for today's conference, Bob Yedid from LifeSci Advisors. Mr. Yedid, you may begin.

Bob Yedid

participating second for conference XXXX all call. you in quarter PolyPid's earnings Thank

the be that months Chief today Chief me the today, call Joining on results financial will XX, PolyPid's Operations. of for and PolyPid released for and Executive PolyPid; Dikla June Ori Officer management website. Warshavsky, release Investors section X the make The XXXX. Operating I'd X U.S. to Earlier ended within of available Officer like is Akselbrad, Czaczkes the A call, copy laws. the of in on remind statements forward-looking federal you the will the company's this press meaning on securities

commercial operations the together the forward-looking partners and with market license clinical example, expectations future of agreement position milestone regarding ADVANZ that filing, of is sufficient Kreos balance, cash making discusses D-PLEXXXX, from loan of from opportunity our proceeds and second additional potential and commercial it upfront timing potential ability XXXX. the maximize trials, end I NDA potential our statements SHIELD For fund MAA payments study submission our our will of with payment ongoing financial of the our under strength the the the potential to PHARMA the from our value through the Europe, the expectation in PHARMA, D-PLEXXXX, to management and results the and ADVANZ when be for top-line quarter

described beyond our time subject in control, are to risks Forward-looking statements risks filings. which uncertainties, to numerous from SEC our of and including the many are time

with actual Accordingly, reliance encourage may forward-looking SEC, Form projections should as any these cause including, identifies and differ new limitation, material events company's as contains XX-F, projections. those statements. to only not place filings which review differ today, in differ without I to and whether factors the uncertainties materially. law, Our revise These you materially from or actual of specific events results statements, that from events. to or PolyPid company's disclaims forward-looking those by cause materially intention that could or involve the the the the The risks financial August results obligation, except you or on undue statements described information speaks XX, live future any time-sensitive otherwise. or broadcast of conference call required or XXXX. results information, because events update to may

over With of completion call prepared remarks, my turn the PolyPid. it's those to pleasure CEO of to Dikla? Dikla, the

Dikla Czaczkes Akselbrad

welcome the time immediately for quarter infections, Under Bob. surgeries agreement Europe, or you total represent PolyPid of payment is to milestones. in SSI, truly agreement On license opportunity potential Thank for an update during of to XXXX D-PLEXXXX at for the to milestones development-related of of upon our upfront and to exciting further team sales we for like call. behalf of terms the you, receive entitled I'm million earnings sales-related provides value substantial a and second D-PLEXXXX in a signing I for million significant an the abdominal corporate to the cardiac to $XX begin to $XX.X validation in the the everyone surgical prevention our with PolyPid. up up PHARMA thrilled potential agreement, additional with site which and for would commercialization of provide such PolyPid, today the of recent signed I will a ADVANZ with exclusive PolyPid. have

extending major site their expertise and in health mainly most one common Intercept, invaluable this important the infections access Surgical surgical the teams on of in open represent up price infections will understand a ADVANZ XX% delivering also will more net much-needed after opportunity Nordic agreement, of recent to it for put licensing active of medical care. receive by We in EU in D-PLEXXXX than is in backed occur and of equity mid-XX%s. major and doubled colorectal across of To royalties private percentages supply and Europe. experienced to D-PLEXXXX such PHARMA SSIs one the in the acquisition in that in to are unmet as excitement XX% double-digit prove marketing is the approved, to negotiated sales the this of Europe. ADVANZ and our a therapies, to need and ADVANZ investors for Capital, resection. to most therapy, countries patients. major to perspective U.K. PHARMA if the D-PLEXXXX hospital-based hospital-acquired medical transfer up PHARMA commercial procedures

We in surgeries selected talking additional the annual X opportunity countries big very the a market Moreover, significant represent about are opportunity. abdominal IQVIA, heart in there market approximately addressable million an year. European to open every also estimated in EU surgeries. big X countries are XXX,XXX X surgeries According the

surprising leading first strategic hospital, partners. deal companies collaborations ideal not Like established staff. in of of strong economics portfolio commercial This have SSI Organization several large clinical Health estimates companies hospital, that approach burden a and per billion the and and PHARMA, that exhibit the current pharmaceutical midsized and relationship U.S. with selling the benefits world. believe infrastructures, The products, estimates that often other economic maintain in significant deep health are commercial the hospital As understanding is we channel these commercialize We D-PLEXXXX our strong to WHO pharmaceutical potential Europe. resulting SSI with up the the traditional step the additional administrative marketed of products represents. a it cost hospital World is medical would in with of rest remain be ADVANZ and in in EURXX to result, dialogue terms of to in year the in

high potential level additional interest of Importantly, there continues D-PLEXXXX be in to partners. a from

critical the will formal determining key objective believe done PHARMA we a in any If the of in most factor. currently transaction, and agreements, is value any executing we the update to value I do there pipeline. U.S. in With we of potential potential agreement. the that, finalize provide maximize the related and collaboration when time additional is of rest be brief ADVANZ of the will to While as on line status world, now additional or maximizing no the D-PLEXXXX have our collaborations D-PLEXXXX

Let's begin abdominal with SHIELD I, our prevention tissue of study soft Phase X D-PLEXXXX the for SSI. evaluating

The XXX the trial minimum we As the year, is this this in in number which enrollment announced recommended the of patients, May concluding targeted Board, or to Monitoring Data DSMB, independent of subsequent the patients study Safety last announced patient XXX the interim protocol. May in This XXXX. on subsequently of by analysis independent from enrolled efficacy of enrollment late recommendation the was patients. was unblinded data the DSMB the based first

surgery X reminder, is to D-PLEXXXX study reduction SHIELD the been in a to between difference demonstrate abdominal control and incisional SSI to of enrolled As in level Israel. the XX of less the least Europe SSI prevention detect XX% compared across the arm, the power approximately alpha XX% designed the I of the Patients in United D-PLEXXXX with States, centers study X.XX. arm in at and arms treatment than an this have in tissue

top and results NDA end only is more Designation, Therapy than enhance trial I from XXXX. largest by rolling in the Full line MAA to anticipated in decade, believe of surgery followed are FDA D-PLEXXXX quarter, targeted the disease conducted data. Importantly, we the by Breakthrough a the eligible which European prevention SHIELD importance start to of Union colorectal Resulting infection potential for submission filing. current is NDA submission early the the

work market Ori? of will for color research we provided X Before financial, for cost we on further key was SSI. completed the PolyPid provide by takeaways how the managing by recent Ori webinar on an this update real-world provide KOLs on our D-PLEXXXX supported in OncoPLEX focused and and recently the commentary U.S.

Ori Warshavsky

Dikla. you, Thank

SSI partnership how we the for fit these will prevention an aiming month, continue preparation to market study other Last explore progress, As discussions practices in-depth understand and within market. research U.S. D-PLEXXXX we practices. launch concluded our current

that indicates even of devastating". few surgical can need reduce the of be market to a specialties procedures and controlled on are and across prevent own based current significant clinical "catastrophic body and is used various experience rates on infection there Our surgeons how primarily treatment a strong institutional types evidence-based research well SSIs studies. and rates infections not surgeons' agree since today protocol regardless of Moreover, all to that bundles unmet by are

personal that Sinai Importantly, within the costly or Dr. they supported would surgeons further last of Goodman have of with XX% participated bundle patients with almost surgeons as latitude research, see SSI has about D-PLEXXXX, that first was patients. cases, a see Mount Kyle a market months, the the surgeon's team Dr. of product a institution and independent infection want to be will that of on their Goodman Much a down not risk of a certain the patients an X webinar control recent Health Dr. Goodman compliance all internal the SSI Cologne detailed use perspective inspection impact of Goodman's or managing to in part their the June. may for investigation followed. Cologne System, they Moreover, population. data the are from D-PLEXXXX standards. all of for perspective. noted outlandish The tracks indicated preventative smokers, infections participated related discussed a because of general research stay use team drilling and and had In that in provided of Dr. infections, can provided comparing in Medical launch, avoiding fit expanding patients profile performance on Center; broader their network fair Cologne and The of will received their that expected including D-PLEXXXX quality prevention USC for a SSI be Dr. performance approximately real know Cologne asked create and BMI bundle understanding IDM their Mount evaluation. it when to Dr. to to SSI infection on in who every market our half with has X time. infections to hospitals approximately amount use prevention rates more infection Sinai's This in hospital of annual the institution bundles. keep An means too believes following bundles. cost money surgeons of faculty practices a is considered that they of individual Health. for are to Elliot data that surgical rate this was and indicated Dr. these view indicated an hospital by to real-world and aspect managing the nothing reported is D-PLEXXXX from at that surgeons before experts, protocol. prevention uncontrolled are appropriate payers. or product on the doctors' measures reimbursement the Dr. When if diabetes, for noted high are patients. readmissions presented room risk financial State who the likely Every study perspective, complications, high at From SSI the triggers peers. reviewing of high example, surgeons the Department why patient their infection, be SSI, looking includes the cost of

it, the are put Goodman office department's principal's baseline. the Dr. over their As rate if to infection called is surgeons

back will reported strict believe Importantly, the commercial currently hand D-PLEXXXX. strong trends to U.S. these due to for in call And we Collectively, indicate infections being I in and process increasingly insights rates the monitoring rising are Dikla. and potential with are place. over that, the

Dikla Czaczkes Akselbrad

Thank you, Ori.

ASCO of area for recently, submission and tumor candidate PolyPid administrated abstract to administrative joined gears, on as of the published OncoPLEX, chemotherapy and make a we compared we have meeting like Switching pleased book. to reduced I Directors. paste discuss were of announce a to progress an the lead continue today the abstract effects in locally XXXX side NDA oncology, that Most our D-PLEXXXX, animal I management that during also changes reoccurrence with potentially team. our product would decreases to systemically agents with prepare Board commercialization in Board to in I'm resection studies applied demonstrating intratumoral potential likelihood surgery. tumor OncoPLEX As targeted

quarter, Certified has in been Senior with PolyPid Vice for Missulawin joining been most increasing finance of Jonny & He Additionally, ability we secured facility responsibility Management, you sheet, a From Ernst and Accounting that and promoted President unique earned Public Financial term broadens in our group, Senior Prior financing of which Bar-Ilan Johnny the an fund options for a in balance on our access from recently of was With to X will to bolsters as he Editor I in further technology Tel-Aviv with as up years capital, platform. to Finance. and MBA an in PLEX nondilutive now D-PLEXXXX significant PolyPid, the in to the $XX from advancement obtained review Israel. University perspective additional has us BA that, our as our our Economics capabilities invest million of will Finance. University in basis Director at roles of Accountant that financials. commercial nondilutive is well loan first provides Young. recall to our

the facility respectively. a X loan $XX the X.X and $X.X As comprised reminder, amount tranches is of of million in million,

will SHIELD in top met. of tranche tranche results be positive analysis obtained first or of was the XXXX, trial April results The drawn and second are tranche from SHIELD available drawn $X.X the if available the interim third final $XX I once million obtaining from to of million the line conditions of was I, other down subject of $X.X million we

our potential As of existing cash, development-related the the that XX, Kreos from $XXX,XXX a we approximately $XX.X action, result top Phase Investors short-term facility. from $X.X to extends announced to from payment additional PHARMA with of milestones sold tranche deposits combined I development-related the of as company XXXX. worth agreement the Also XXXX. as $X.X cash loan quarter shares end loan X in $XX.X the had Capital, line XXXX, balance at-the-market the study the PHARMA ADVANZ cash million ADVANZ note of contingent our of upfront was sheet the runway it and of This runway drawn July equivalents our excludes throughout up with potential excluding to million, of payment cash this second and from relates the including million June second of XXXX, SHIELD of should which and positive we quarter week, upon additional million. last second during milestones of up ordinary

expense statement. XXXX business X expenses in XX, of [Technical recorded Now period XXXX. were I let's modestly the development expenses for compared expenses development June the million increase and million SHIELD increased $X.X period were up $X.X turn the $XXX,XXX second prior the in primarily the Research Difficulty] for X-month Phase XXXX, income to our were in ended the The resulted months cost to R&D in X to and XXXX. clinical compared from administrative to trials. the the Marketing $XXX,XXX, and of period. for quarter $X.X as XXXX for same in second quarter of million compared year General million $X.X same

of quarter clinical the For loss to the of trial. compared $XX.X period. as $XX.X by rate second the had Phase XXXX, of driven in X recruitment was SHIELD strong primarily million a company million patient in This year the a prior I

We will your now questions. the open Operator? call to

Operator

Gary question comes Markets. [Operator the Nachman Instructions] line first Capital from of Your from BMO

Gary Nachman

Okay. Great. all Congrats on progress. the

the capabilities be they the initially in opportunities and Will market ADVANZ with there? countries in agreement when exact on time about license the space What those their countries? to file Europe. What And in are more Europe? will expecting the just the So, it the same you criteria as U.S.? in focus are Europe, talk hospital in

Dikla Czaczkes Akselbrad

capability, is where general also of strategically business last sales increased where Nordic hospital sales force the medical weeks doubled in anti-infective -- Fund-backed buying Europe force targeting. company. of just products. They U.S. out focused ago dramatically in a specialty were Fund specialty only in their they very They $XXX PHARMA million, are the quite space, built a This a -- of And is They few that's all and Intercept. Nordic bought ADVANZ nice Europe. spot. their about have in have the products. and access year force And they for by sweet on they are X their on is this

personnel they hundreds with of access Europe. a reps now are few sales So market and in

Of of learned from the what perspective and much right patients course, product Eastern countries and right but Western the and very in our Europe D-PLEX a we've together to want so negotiation, the big in the the like more focused very in the to doors from and worked where few last [talks] be versus and much physicians. Europe, on for to and X months open we

Gary Nachman

[Technical filing, timing that? Okay. of the And then, Difficulty] the

Dikla Czaczkes Akselbrad

the should review We're to and probably about both the time, time more a less So, of time. at slightly be is more time. then again, different Europe the after. same But The is the or approval in distribute differently. process and in filing quarter is maybe at of more filing in not than expected the the bit talking filing the review. But less difference a we're terms or looking time same be same generally filing. And the way

Gary Nachman

Okay. factors early are just additional next there for up? data the then, gating it's that to you're in will year, supplement U.S., when CMC data it rolling the that going if any I side, buttoned clinical And package? And the outside submission on is in is initiated of SHIELD -- going be there to that completed? be in all any And

Dikla Czaczkes Akselbrad

later with start the I'll So part.

in [one]. having got expected So, and we more capacity. Everything yes, GMP is which place. the model. X-month facility have months, get the we will year. data start, on clinical in I remember seen the with we to first ready call X and our the should and than in in in be all from X last are rolling There also will as the submission manufacturing stability. our not are aspects again, X, that The CMC, we submitting start few year, and mentioned, the in last have I'm early the for more some stability increased submitting assumption where that getting that of than And and part process you validated are the everyone trial, submitted. we models of Phase Phase Phase to this our for X they've so is sure are is can be those terms manufacturing will our doubled to required supporting be be model, last capacity months process, the already stage is that development And -- be the SHIELD prepared the the FDA agreement process and that

So that the on to track. model right this probably But last be you're again, this be submitted. is, will

Gary Nachman

last That's helpful. Okay. then, Ori. for question, the And probably

and about U.S.? think partnership U.S. like think have potentially sort is it how that you ongoing. different And the Do in And a discussions there or just the out you'll preparing the that, in big some are commercial of more how the be have? of scenarios you thinking when sounds licensing would of what presence willing less opportunity in Just that you're it launching you completely U.S.? for presence terms are you're of of or in the some commercial likely co-promote to

Ori Warshavsky

it's for -- keep attention focus that us. U.S. market. believe to That's where us and It's in level think, biggest or is. the our I the of for market we important control our the product in U.S. some the

so, for partner a co-promote, and find licensing. not And to strategy the is

We developing more lot we around And activities a see all, the the around knowledge How some the lot of deal of are the bring of do the product deal And A needed we on We into partner, manufacture depend backward manufacturing progresses, on of time prelaunch are will structure and ADVANZ. So, this. product. but like and the the medical we look that a bring will we're with -- launch. this like? first build not capabilities more the lot bring as the and since products. the discussion in to the of look we would knowledge need. of integrated this it the of

of it's label to who positioned, strategy, be so call will on the strategically, on. some I us definitely brand it on, level on product expand partner. the to to dependent important control how the the how day, have the on control at But pricing, of or think the is we end we and

this know what that way And in, then, end up. for P&T looking depending how around the the comes the on the will suite. is partners are partner around the structure around surgery committees, We think I hospital,

Gary Nachman

Okay. Great.

Operator

line And the question Fitzgerald. Folkes comes Brandon the from from of Cantor

Brandon Folkes

between U.S.? by how all opportunity. similarly, how in talk on question the this compares on Congratulations the the in the country of countries? about may to the you new Maybe standard just U.S. Can progress. And care on from in country differ rates how that infection to in does terms EU, compare and maybe of just Europe maybe following the and

Dikla Czaczkes Akselbrad

Yes, sure.

also our major Generally, slightly basis specific Europe I in broad need open We countries, the in that our see would as the U.S., XX%. XX% you infection and seen there understanding, in but that to the historical in you see higher much research countries was at might an within on the you'll what XX% to procedure, so saw at average when that deal. this as it between a difference difference. in see X Europe of general, to colorectal looking this So, -- Europe. yet, especially different also in XX%, experience market don't be done than such you was we'll Phase in what's look in very we data, part in the can could tell again, see rate -- you surgery, is

is in of level have the Europe. Eastern you not they don't well, surgical site It's infection, say, U.K., will that it everywhere. see You infection the in only

are So, that in geographic slight as there major hospital just to it's this the at XX% XX% will in between average Europe. in And differences the numbers also between not the some occur all of is all. Obviously this to countries. and see U.S., procedures, hospital, you surgical

Brandon Folkes

do side II D-PLEX is approval? initially? exposures then, the be Phase is you sNDA? you to, a II, you to the FDA SHIELD the that us potentially And what's think in for to very the at just the broader the SHIELD do given hear expectation talking there's any one and label And But SHIELD question, label I I I Or as in did remind submit Great. explore Dikla, meeting agreed you may. much if -- maybe potential submitted. more of in Can should at just say, X put about you have could the it and an think pre-NDA we we exposures of that

Dikla Czaczkes Akselbrad

into is very are of we This putting question. preparing lot that. And for a a good effort

with U.S. -- this there needed We II, are sorry, gathered, between the a FDA, if MMA of will be us this is some that the could and be that months' and was forward. MIA. slight time we much is you the differences to. are terms NDA, extend have SHIELD and that both expect And we in post-NDA agreed are level. what to approval few data for some this a a very indication preparing path Europe -- And that is aiming on are already the a backup. indications submitted what believe mentioned, in as a backup and target, broad we But with to broad what have that but this Difficulty] we We [Technical with we received abdominal aiming is a reasonable also

labeling So, II, plan external But to give then to data and we until broad that other reasonable be we it's can the in is plan think for this indications. wait We'll at just beyond a there get will a could quarter is something have but based or also abdominal broad for what the within we top This the it. for see discuss SHIELD submission, again, more we I on later are aiming very already hundred, possibility submitted orthopedic bit XXX patients And we a is abdominal a few get add that expanding of a NDA that will indication. this we going X, that too short-term. broad and much feasible additional early the of on, on the end X and level. broad forward. line, the There

Operator

the The Wilbur Raymond line from of question James. Elliot from comes

Michael Parolari

This on is Michael for actually Parolari Elliot.

that is opportunity? how impacting know you But opportunity about guys detailed EU different off, reviewing any ADVANZ terms U.S. in So, the commercial a Europe. key to bringing way might there is partner to targeting that little perspectives you reimbursement the the that's in and the start of your background you're of pricing bit I or the table view

Ori Warshavsky

take Michael, maybe I Maybe can -- one. this

So, -- we range further when like when pricing, the $XXX, with some you as in remind administered somewhere just This ZYNRELEF. vial broad proxy is of what products pricing restriction surgeons. research $XXX at looked $XXX of look at tested local heard no saw to everyone, per and $XXX that and from out the per the U.S., to to we in And EXPAREL we tested with at between vial the we news. of came -- kind research other what from is --

number this the slightly Our is assumption. your assumption in as $XXX That's an does think, lower same, sharpen to be probably Europe research -- sure a in is this lower. we you'll that I assuming able prelaunch prices see of our and now, will I'm assumption -- and be more. kind well assumption. ADVANZ slightly I'm But activities as as the for our going than on we'll But good work

the structure, are for getting first, all In working activities, -- is That from doing responsible terms of access it, and we the call including said, commercial let's or a, the access deal just ADVANZ point, together. so reimbursement.

with of will a developed health together plan data economics be We the countries on piece, the in as in executed know, There's trial. in the bigger work together collecting for and as European will generating pharma some is the we're which a of part And U.S. piece, economics ADVANZ. place which, the than driver we

Michael Parolari

secondary also towards I, anticipating should the of primary [that That's helpful. we endpoint, be any then, the SHIELD redo]? looking endpoints line the it. updates key but on expected And obviously readout top Got on along on with any readout expecting a

Dikla Czaczkes Akselbrad

Yes.

both endpoint. So the line top first and we have the are expecting to secondary

on months' we infection. the few key will key just secondary full CSR. be point, reminder, both secondary point. end time, primary able the the a to The infection And and So and we'll as just probably first have is within mortality also both update a end it's

Michael Parolari

and the on is, program you last points able it. prepared any expect of year-end one OncoPLEX for should thinking see and you before we your Got being me further wondering then to D-PLEX guys program get remarks. guys as I just shift But update how of know progress are an And to provided you if commercialization closer in that to the evolving attention there. some

Dikla Czaczkes Akselbrad

the update and to year. say of at before that the I'm on time So able resources the have after very a company the the much in and of again, will of plan now, progressed steps this personal cleaning X able time a nicely. this be on level trial. approval and here me to last more we And of It's we very And before and that top terms well a for D-PLEXXXX company for very sure But soon to effort this hoping much year. we that both much on as it years. you us end a those more results, really we to line, here aggressively. will as be all meeting also large stage more is robust end trigger I line will as substantial very as But to and the much, having that enable people very on concentrated OncoPLEX. we of course, small and are were obviously, will progress say manufacturing. be if more are this to I next reasons, will focused has is happening hard very and must the the top OncoPLEX relatively attention, line, able share plan required the the hope on, the said, just And And as what in day have was which the data for

Operator

the line from of from Barclays. comes Balaji question the And Prasad

Unidentified Analyst

actually Balaji. is for [Mikaela] on This

Just been there expect competitive has update use of on guess then, the of new I new this? guess, X on just with case things, any to for just similar side D-PLEX And an I me. ongoing to just any when we timing conversations, guess or the partnership potential entrants? on back circling developments -- I updates can

Dikla Czaczkes Akselbrad

on competition You to to the Ori, take part, dialogues and relate the I take want and us discussions you'll additional commercialization. will --

Ori Warshavsky

the make players expect evidence, in data we we have the size SHIELD the market of me get that competition, the I. the on so of see what point let [Mikaela], significant from don't the that Yes. today, existing to trial, first, even level maybe that

So compare exist really have level top standard when that remind, compare what the of a they on evidence. care. of of of That to of prevention measures tools don't to we the is trial D-PLEX you what from today, the just really type said,

tools or of competitors. today procedures So, are their that as SSI. or exist are at the not that bundles in preventing prevention away changing behavior first from direct used for none doctor's the measures a anything taking go, the We're the least

that into as in we nothing but pipelines, FDA as that's the the trials. horizon, Looking far we small clinical in see There in prevention, SSI literature everything tell, in in are the don't even in is databases or really midterm preclinical can anything attempts horizon. near-term

Dikla Czaczkes Akselbrad

it we presence can the discussions this that of in. we timing, less think that will of of sense I additional the top And I and what -- are from summer. to record to partnerships timing the do commercialization, those months again we to But not Obviously than dialogues actual the this is of them, able on imply expect aspect actual already giving we being on the and partnership accelerate that already future say, collaboration, regards be some that line. this with do X and on sense track obviously the have established announce doesn't that we the think

on this say at that's can I think the I thing timing. only stage

Operator

question comes JMP the from Our next Buchanan Securities. of from Roy line

Roy Buchanan

powering Dikla, less one, First mentioned X.XX. alpha the than and you the

So statistically be if could for the minimum significant. us to is tell was wondering you needed endpoint just the what threshold primary I

Dikla Czaczkes Akselbrad

very X.X% you X.XXX%, [X.XXX% -- to the had one, below X.XXX], below we -- very The penalty that pay much. yes, you so actual interim, is can mean, the minimal, see, X.XXX%. The for as

Roy Buchanan

know on you've partnerships mentioned I the to had And partnering discussion of as you OncoPLEX. just I molecules call, as you then, with well companies platform. at other stretch But sorry before. the beyond last kind looking And potentially their had think OncoPLEX

look Halozyme little platform And thoughts something like future out a with what could So more on in if molecules. bit. does proprietary partnering broadly, you just partner I wondered maybe any the maybe the

Dikla Czaczkes Akselbrad

feasible peptides, possible at proprietary and also molecules, platform approach. novel pipeline, platform vision things. our and the from most are is be and FLEX explore and the not And aiming that's is from additional that is think the So, with this all to value collaborating we're look our but to we extract also the for vision when to PolyPid like antibodies could of own approach. where really our have really part we way just the or here we This vision their believe in the I and would

If had preclinical commercial I be those of X in give some think they this that which oncology additional opposed additional as we'll platform. is stage of terms road top that much and some and our what the door data the kind from the purely additional of from investors that, think probably progress will of have to open program, research, of first, line, OncoPLEX, kind and to ago, map the the need we'll you and the for have licensing take aspects something I to this X, years I collaboration we time. mature will those But collaborations. was the will more

Operator

further no are There questions.

to remarks. back the to like I'd conference for closing So speakers the hand

Dikla Czaczkes Akselbrad

quarter second are call. for you have how Thank the to emphasize like earnings our conference we would we to-date. about I excited progress achieved joining

as of our by all D-PLEX milestone from and grateful for you organization we their sales external bringing on a potentially to and with members our achieving forward patients royalties D-PLEXXXX well commitment in to to towards shortly call. as look European As to partners payments partner, we research next transform care a from our our remain health our again as possible. speaking company and to commercial We of goal development team mission earning providers their continuing to as quickly our and support advance and

Operator

This concludes today's conference call.

now may You disconnect.

PolyPid (PYPD) 11 Aug 222022 Q2 Earnings call transcript